2008
DOI: 10.5858/2008-132-1683-efdcs
|View full text |Cite
|
Sign up to set email alerts
|

Extranodal Follicular Dendritic Cell Sarcoma

Abstract: Extranodal follicular dendritic cell sarcoma is a rare tumor of follicular dendritic cells that can occur in a wide variety of sites. Although fairly well characterized histologically, with a distinct immunophenotype, it remains underrecognized, with as many as one third of cases initially misdiagnosed. This is often due to a failure to consider the entity. Patients with this tumor may have a worse prognosis than originally described. Prompted by a recent case at our institution, we briefly review the clinical… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
32
0

Year Published

2009
2009
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 46 publications
(32 citation statements)
references
References 25 publications
0
32
0
Order By: Relevance
“…Follicular dendritic cell sarcoma has a slight female predominance (1.2:1) and a wide patient age range for disease presentation, although it most often presents in the fifth decade of life. 2 The World Health Organisation classification of haematopoietic and lymphoid neoplasms includes FDCS in the group of histiocytic and dendritic cell neoplasms. 5 Because of the rarity of dendritic cell sarcoma (DCS), its clinical behaviour and optimal management has not been consolidated.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Follicular dendritic cell sarcoma has a slight female predominance (1.2:1) and a wide patient age range for disease presentation, although it most often presents in the fifth decade of life. 2 The World Health Organisation classification of haematopoietic and lymphoid neoplasms includes FDCS in the group of histiocytic and dendritic cell neoplasms. 5 Because of the rarity of dendritic cell sarcoma (DCS), its clinical behaviour and optimal management has not been consolidated.…”
Section: Discussionmentioning
confidence: 99%
“…1 Follicular dendritic cells are immune accessory cells widely distributed in both nodal and extranodal lymphoid tissue, presenting antigens to B-lymphocytes. 2 Thus, uncontrolled proliferation of these cells affects lymph nodes, primarily of the mediastinum and cervical and axillary regions. 3 When primary extranodal disease occurs, the pharyngeal region is one of the preferred sites, in particular the tonsils.…”
Section: Introductionmentioning
confidence: 99%
“…[ 12 , 25 ] The differential diagnosis include: sarcoma, Hodgkin disease, leiomyosarcoma, gastro-intestinal stromal tumor (GIST), and inflammatory pseudo-tumor. [ 8 , 26 , 27 ] According to IHC analyses, FDC sarcoma shows spindle tumor cells arranging in fascicular or storiform patterns, which are immuno-reactive for one or more FDC markers: CD21 (C3d receptor, positive in 93% of cases) and CD35 (C3b receptor, positive in 89% of cases). Other quite specific markers used are: R4/23 (63%), Ki-67 (5–50%), EMA (41%), Vimentin (61%), HLA-DR (57%), CD45 (21%), and S-100 protein (31%).…”
Section: Discussionmentioning
confidence: 99%
“…By now, there are less than 100 cases of follicular dendritic cell tumors have been reported in the English literature [2,9]. The differential diagnosis includes Hodgkin's disease, sarcoma, leiomyosarcoma, gastrointestinal stromal tumor and in ammatory pseudotumor [10][11][12]. According to immunohistochemical analyses, the most commonly used FDC tumor markers include CD21 (C3d receptor, positive in 93% of cases) and CD35 (C3b receptor, positive in 89% of cases).…”
Section: Discussionmentioning
confidence: 99%